Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report

<p>Abstract</p> <p>Introduction</p> <p>Mastocytosis is a rare disease consisting of a group of disorders characterized by a pathologic increase in the number of mast cells in one or more organ system. Treatment is symptomatic. Oral sodium cromoglicate (SCG) is the only...

Full description

Bibliographic Details
Main Authors: Hagberg Hans, Edwards Alan M
Format: Article
Language:English
Published: BMC 2010-06-01
Series:Journal of Medical Case Reports
Online Access:http://www.jmedicalcasereports.com/content/4/1/193
id doaj-c71e344ab16247ee8698753ff49eae08
record_format Article
spelling doaj-c71e344ab16247ee8698753ff49eae082020-11-24T23:28:39ZengBMCJournal of Medical Case Reports1752-19472010-06-014119310.1186/1752-1947-4-193Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case reportHagberg HansEdwards Alan M<p>Abstract</p> <p>Introduction</p> <p>Mastocytosis is a rare disease consisting of a group of disorders characterized by a pathologic increase in the number of mast cells in one or more organ system. Treatment is symptomatic. Oral sodium cromoglicate (SCG) is the only treatment licensed for the treatment of mastocytosis. In this case we report how in a mastocytosis patient being treated with H<sub>1 </sub>and H<sub>2 </sub>antihistamines, and oral sodium cromoglicate, the addition of inhaled sodium cromoglicate resulted in further improvement. This is the first report of this use of the drug in this disease.</p> <p>Case presentation</p> <p>The subject is a Caucasian woman aged 40 years. Symptoms of mastocytosis began when she was aged 13 years, but the diagnosis was not made until after her first pregnancy aged 33 years. Symptoms improved with H<sub>1 </sub>and H<sub>2 </sub>antihistamines, and oral sodium cromoglicate, but it required the addition of inhaled sodium cromoglicate to produce further improvement, specifically in the symptoms of bone pain, fatigue and headache. Doses of oral sodium cromoglicate had to be increased if challenged with a food to which the subject was sensitive. Doses of inhaled sodium cromoglicate had to be increased during the menstrual period.</p> <p>Conclusions</p> <p>Patients suffering from the rare disease of mastocytosis have symptoms affecting many body systems. Symptoms result from the release of inflammatory mediators from mast cells. Sodium cromoglicate, a drug that reduces the release of mediators from mast cells, is effective in controlling gastrointestinal symptoms, but less effective in those affecting other body systems. In this case report we have shown that the addition of inhaled sodium cromoglicate controls the symptoms of bone pain, fatigue and headache and also that the doses have to be increased during the menstrual period.</p> http://www.jmedicalcasereports.com/content/4/1/193
collection DOAJ
language English
format Article
sources DOAJ
author Hagberg Hans
Edwards Alan M
spellingShingle Hagberg Hans
Edwards Alan M
Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report
Journal of Medical Case Reports
author_facet Hagberg Hans
Edwards Alan M
author_sort Hagberg Hans
title Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report
title_short Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report
title_full Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report
title_fullStr Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report
title_full_unstemmed Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report
title_sort oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report
publisher BMC
series Journal of Medical Case Reports
issn 1752-1947
publishDate 2010-06-01
description <p>Abstract</p> <p>Introduction</p> <p>Mastocytosis is a rare disease consisting of a group of disorders characterized by a pathologic increase in the number of mast cells in one or more organ system. Treatment is symptomatic. Oral sodium cromoglicate (SCG) is the only treatment licensed for the treatment of mastocytosis. In this case we report how in a mastocytosis patient being treated with H<sub>1 </sub>and H<sub>2 </sub>antihistamines, and oral sodium cromoglicate, the addition of inhaled sodium cromoglicate resulted in further improvement. This is the first report of this use of the drug in this disease.</p> <p>Case presentation</p> <p>The subject is a Caucasian woman aged 40 years. Symptoms of mastocytosis began when she was aged 13 years, but the diagnosis was not made until after her first pregnancy aged 33 years. Symptoms improved with H<sub>1 </sub>and H<sub>2 </sub>antihistamines, and oral sodium cromoglicate, but it required the addition of inhaled sodium cromoglicate to produce further improvement, specifically in the symptoms of bone pain, fatigue and headache. Doses of oral sodium cromoglicate had to be increased if challenged with a food to which the subject was sensitive. Doses of inhaled sodium cromoglicate had to be increased during the menstrual period.</p> <p>Conclusions</p> <p>Patients suffering from the rare disease of mastocytosis have symptoms affecting many body systems. Symptoms result from the release of inflammatory mediators from mast cells. Sodium cromoglicate, a drug that reduces the release of mediators from mast cells, is effective in controlling gastrointestinal symptoms, but less effective in those affecting other body systems. In this case report we have shown that the addition of inhaled sodium cromoglicate controls the symptoms of bone pain, fatigue and headache and also that the doses have to be increased during the menstrual period.</p>
url http://www.jmedicalcasereports.com/content/4/1/193
work_keys_str_mv AT hagberghans oralandinhaledsodiumcromoglicateinthemanagementofsystemicmastocytosisacasereport
AT edwardsalanm oralandinhaledsodiumcromoglicateinthemanagementofsystemicmastocytosisacasereport
_version_ 1725548508516188160